BBVA
VRTX icon

Banco Bilbao Vizcaya Argentaria’s Vertex Pharmaceuticals VRTX Stock Holding History

Banco Bilbao Vizcaya Argentaria’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.7M Sell
39,809
-969
-2% -$429K 0.12% 133
2026
Q1 		$18.1M Sell
40,778
-53,059
-57% -$24.7M 0.13% 131
2025
Q4 		$42.6M Sell
93,837
-4,316
-4% -$1.86M 0.3% 65
2025
Q3 		$38.4M Buy
98,153
+4,464
+5% +$1.87M 0.29% 64
2025
Q2 		$41.7M Sell
93,689
-4,532
-5% -$2.09M 0.38% 47
2025
Q1 		$47.7M Buy
98,221
+10,425
+12% +$4.86M 0.48% 37
2024
Q4 		$35.4M Sell
87,796
-4,531
-5% -$2.1M 0.37% 49
2024
Q3 		$42.9M Buy
92,327
+11,926
+15% +$5.73M 0.43% 42
2024
Q2 		$37.7M Sell
80,401
-37,844
-32% -$16.4M 0.4% 45
2024
Q1 		$49.4M Buy
118,245
+1,447
+1% +$612K 0.57% 33
2023
Q4 		$47.5M Sell
116,798
-16,646
-12% -$6.15M 0.56% 34
2023
Q3 		$46.3M Sell
133,444
-1,632
-1% -$571K 0.62% 29
2023
Q2 		$47.5M Buy
135,076
+1,542
+1% +$520K 0.62% 28
2023
Q1 		$42.1M Buy
133,534
+4,042
+3% +$1.21M 0.52% 42
2022
Q4 		$37.4M Buy
129,492
+4,697
+4% +$1.43M 0.55% 36
2022
Q3 		$36.1M Buy
124,795
+45,286
+57% +$13M 0.58% 33
2022
Q2 		$22.4M Buy
79,509
+6,657
+9% +$1.78M 0.34% 70
2022
Q1 		$19.7M Sell
72,852
-1,787
-2% -$424K 0.27% 84
2021
Q4 		$16.6M Buy
74,639
+49,830
+201% +$9.69M 0.22% 93
2021
Q3 		$4.51M Sell
24,809
-837
-3% -$163K 0.07% 235
2021
Q2 		$5.31M Buy
25,646
+8,853
+53% +$1.85M 0.09% 197
2021
Q1 		$3.59M Sell
16,793
-4,729
-22% -$1.04M 0.07% 247
2020
Q4 		$5.09M Buy
21,522
+10,374
+93% +$2.38M 0.12% 159
2020
Q3 		$3.03M Buy
11,148
+3,019
+37% +$833K 0.09% 207
2020
Q2 		$2.36M Sell
8,129
-2,827
-26% -$766K 0.08% 220
2020
Q1 		$2.61M Buy
10,956
+592
+6% +$136K 0.09% 214
2019
Q4 		$2.27M Buy
+10,364
New +$2.1M 0.07% 289

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Banco Bilbao Vizcaya Argentaria's VRTX Position: Q2 2026 in Review

Banco Bilbao Vizcaya Argentaria reduced its Vertex Pharmaceuticals (VRTX) stake by 2.4% in Q2 2026, selling an estimated $429K and leaving 39,809 shares worth $19.7M. The position accounts for 0.12% of the portfolio, ranked #133.

Banco Bilbao Vizcaya Argentaria first reported a position in VRTX in Q4 2019 and has held it in 27 quarters since. The position peaked at $49.4M in Q1 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Banco Bilbao Vizcaya Argentaria held 39,809 shares of Vertex Pharmaceuticals worth $19.7M as of Q2 2026.
  • Banco Bilbao Vizcaya Argentaria sold 969 Vertex Pharmaceuticals shares in Q2 2026, an estimated $429K.
  • Vertex Pharmaceuticals made up 0.12% of Banco Bilbao Vizcaya Argentaria's portfolio in Q2 2026, its #133 holding.
  • Banco Bilbao Vizcaya Argentaria first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Banco Bilbao Vizcaya Argentaria's Vertex Pharmaceuticals position peaked at $49.4M in Q1 2024.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Banco Bilbao Vizcaya Argentaria's 13F filing for Q2 2026, filed 12 Aug 2026.